Blaine Davis
CIK 1802188 · Chief Financial Officer · last filed 2026-01-08
Blaine Davis is a Chief Financial Officer who has filed 12 SEC Form 4 insider transactions across 3 companies since 2020. The most recent filing shows the insider sold $72.2K of RNAC on Jan 8, 2026. Across all open-market trades the lifetime net is −$181.2K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $829.9K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
RNAC price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
1 LITTLE WEST 12TH STREET
NEW YORK, NY 10014
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RNAC | Chief Financial Officer | 121,220 | $6.42 | $778.2K | -$206.3K | 6 | 2026-01-08 |
| Cartesian Therapeutics, Inc. (SELB) Delisted | Chief Financial Officer | — | $0.88 | — | $0 | 1 | 2022-11-30 |
| TARA | Chief Financial Officer | 20,662 | $2.50 | $51.7K | $25.0K | 5 | 2022-07-19 |
Recent Filings
12 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-01-08 | RNAC | Sell (S) | −10,591 | -$72.2K | EDGAR |
| 2026-01-06 | RNAC | Grant (A) | +37,000 | $0 | EDGAR |
| 2025-01-07 | RNAC | Sell (S) | −7,989 | -$134.0K | EDGAR |
| 2025-01-06 | RNAC | Grant (A) | +22,000 | $0 | EDGAR |
| 2024-01-04 | RNAC | Grant (A) | +2,424,000 | $0 | EDGAR |
| 2023-11-15 | RNAC | Disp (D) | — | $0 | EDGAR |
| 2022-11-30 | Cartesian Therapeutics, Inc. (SELB) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-07-19 | TARA | Tax (F) | −5,081 | -$15.9K | EDGAR |
| 2022-01-05 | TARA | Grant (A) | +14,100 | $0 | EDGAR |
| 2021-01-21 | TARA | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.